公开(公告)号：WO2005039578A3

公开(公告)日：2005-09-29

申请号：PCT/NL2004000760

申请日：2004-10-29

Applicant: AZ UNIV AMSTERDAM ,  AERTS JOHANNES MARIA FRANCISCU

Inventor： AERTS JOHANNES MARIA FRANCISCU

IPC: A61K31/445 ,  A61P3/10

CPC classification number: A61K31/445

Abstract: The invention relates to the use of a deoxynojirimycin derivative, or pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of insulin resistance, hyperpigmentation and/or inflammatory processes in the skin, a fungal disease, overweight and obesity, or a microbacterial infection.

Abstract translation: 本发明涉及脱氧野ri霉素衍生物或其药学上可接受的盐在制备用于治疗皮肤中的胰岛素抵抗，色素沉着过度和/或炎性过程，真菌病，超重和肥胖症或者 微生物感染。

公开(公告)号：WO03074685A2

公开(公告)日：2003-09-12

申请号：PCT/NL0300170

申请日：2003-03-07

Applicant: AZ UNIV AMSTERDAM ,  VAN DEVENTER SANDER JAN HENDRI ,  VAN MONTFRANS CATHARINA

Inventor： VAN DEVENTER SANDER JAN HENDRI ,  VAN MONTFRANS CATHARINA

IPC: A61K48/00 ,  C07K14/54 ,  C12N5/06

CPC classification number: C07K14/5428 ,  A61K48/005 ,  C12N2510/02

Abstract: The present invention to methods for producing mononuclear cells overexpressing IL-10. The method comprises the ex vivo introduction of an expression construct comprising a nucleotide sequence encoding a polypeptide having IL-10 activity into peripheral blood mononuclear cells of a subject. The thus obtained peripheral blood mononuclear cells have an altered phenotype as a result of the expression of an introduced IL-10 transgene. In particular the invention relates to CD4+ T cells that functionally behave as regulatory T cells as a result of the expression of an IL-10 transgene. The IL-10 transgenic mononuclear cells may be used to treat a variety of inflammatory diseases, particularly T helper 1-mediated inflammatory diseases.

Abstract translation: 本发明涉及生产过表达IL-10的单核细胞的方法。 该方法包括将含有编码具有IL-10活性的多肽的核苷酸序列的表达构建体体外引入受试者的外周血单核细胞。 由此获得的外周血单核细胞由于引入的IL-10转基因的表达而具有改变的表型。 特别地，本发明涉及作为IL-10转基因表达的结果，功能上表现为调节性T细胞的CD4 + T细胞。 IL-10转基因单核细胞可用于治疗各种炎性疾病，特别是T辅助1介导的炎性疾病。

公开(公告)号：WO2011105900A3

公开(公告)日：2011-11-17

申请号：PCT/NL2011050130

申请日：2011-02-23

Applicant: AZ UNIV AMSTERDAM ,  FLUITER KEES ,  BAAS FRANK

Inventor： FLUITER KEES ,  BAAS FRANK

IPC: C12N15/113 ,  A61K31/7088 ,  A61K31/712 ,  A61P37/06

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61K31/712 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341

Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement component 8-alpha (C8-alpha). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal.

Abstract translation: 公开了旨在抑制或阻断哺乳动物补体成分8-α（C8-α）的表达的拮抗剂​​。 本发明具有广泛的用途，包括用于制备用于增强哺乳动物急性或慢性神经损伤后神经再生的药物。

公开(公告)号：WO2009078712A3

公开(公告)日：2009-08-13

申请号：PCT/NL2008050804

申请日：2008-12-17

Applicant: UNIV AMSTERDAM ,  HELLINGWERF KLAAS JAN ,  TEIXEIRA DE MATTOS MAARTEN JOO

Inventor： HELLINGWERF KLAAS JAN ,  TEIXEIRA DE MATTOS MAARTEN JOOST

IPC: C12N1/20 ,  C07K14/195 ,  C12N15/74 ,  C12P5/02 ,  C12P7/04 ,  C12P7/06 ,  C12P7/16 ,  C12P7/18 ,  C12P7/20 ,  C12P7/24 ,  C12P7/28 ,  C12P7/56

CPC classification number: C12P7/56 ,  C12N1/20 ,  C12N15/74 ,  C12N15/82 ,  C12P5/026 ,  C12P7/04 ,  C12P7/06 ,  C12P7/065 ,  C12P7/16 ,  C12P7/18 ,  C12P7/20 ,  C12P7/24 ,  C12P7/28 ,  C12P7/30 ,  Y02E50/10 ,  Y02E50/17

Abstract: A process of producing an organic compoundand/or an intermediary compound as defined herein by feeding carbon dioxide to a culture of a cyanobacterial cell and subjecting said culture to light, wherein said cell is capable of expressing a nucleic acid molecule, wherein the expression of said nucleic acid molecule confer on the cell the ability to convert a glycolytic intermediate into said organic compound and/or into said intermediary compound and wherein said nucleic acid molecule is under the control of a regulatory system which responds to a change in the concentration of a nutrient in said culture.

Abstract translation: 通过将二氧化碳供给至蓝细菌细胞的培养物中并使所述培养物发光来生产如本文所定义的有机化合物和/或中间化合物的方法，其中所述细胞能够表达核酸分子，其中所述 核酸分子赋予细胞将糖酵解中间体转化成所述有机化合物和/或转化成所述中间化合物的能力，并且其中所述核酸分子处于响应营养物浓度变化的调节系统的控制下 在所述文化中。

公开(公告)号：WO2008115054A2

公开(公告)日：2008-09-25

申请号：PCT/NL2008050150

申请日：2008-03-17

Applicant: UNIV AMSTERDAM ,  VERSCHURE PERNETTE JEANINE ,  BRINK MAARTJE CAROLIEN

Inventor： VERSCHURE PERNETTE JEANINE ,  BRINK MAARTJE CAROLIEN

IPC: C12Q1/68 ,  C12N15/79

CPC classification number: C12N15/1086 ,  C12Q1/6876 ,  C12Q2565/549 ,  C12Q2545/114

Abstract: The present invention relates to methods for inducing changes in epigenetic gene control in a chromatin domains in eukaryotic cells, and to nucleic acid constructs and host cells for use in such methods. The methods use nucleic acid constructs that are preferablyintegrated at a predetermined chromatin region of the host cell's genome, which nucleic acid construct comprise binding sites for a DNA-binding protein. Proteins that induces or are suspected to induce epigenetic gene control may then be targetedtothe integrated nucleic acid construct by means of fusion to the DNA binding protein. The targeting protein that induces or is suspected to induce epigenetic gene control to the integrated nucleic acid construct then allows to determine its effects on chromatin structure, gene expression, and epigenetic status of the chromatin locus.

Abstract translation: 本发明涉及用于诱导真核细胞染色质结构域中的表观遗传基因控制变化的方法，以及用于这些方法的核酸构建体和宿主细胞。 所述方法使用优选整合在宿主细胞基因组的预定染色质区域的核酸构建体，该核酸构建体包含DNA结合蛋白的结合位点。 诱导或怀疑诱导表观遗传基因控制的蛋白质可以通过与DNA结合蛋白融合而被靶向整合的核酸构建体。 诱导或怀疑对整合的核酸构建体诱导表观遗传基因控制的靶向蛋白质允许确定其对染色质基因座的染色质结构，基因表达和表观遗传状态的影响。

公开(公告)号：WO2004048408A8

公开(公告)日：2005-08-04

申请号：PCT/NL0300831

申请日：2003-11-25

Applicant: AZ UNIV AMSTERDAM ,  PEPPELENBOSCH MAIKEL PETRUS ,  ZIVKOVIC DANICA ,  DIKS SANDER ,  BINK ROBERT JOZEF

Inventor： PEPPELENBOSCH MAIKEL PETRUS ,  ZIVKOVIC DANICA ,  DIKS SANDER ,  BINK ROBERT JOZEF

IPC: C07K14/47 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/0797 ,  C12N5/06 ,  C07K14/435 ,  C07K14/46

CPC classification number: C12N5/0623 ,  C07K14/47 ,  C12N2501/40 ,  C12N2501/41

Abstract: The present invention relates to methods for expansion of stem or progenitor cells. These methods rely on Asb-a polypeptides or nucleic acids to temporarily suppress differentiation of the cells, thus allowing proliferation and self-renewal of the stem or progenitor cells. Abs-a polypeptides and coding sequences define a class of polypeptides and nucleic acids that are both structurally and functionally highly conserved among vertebrates. Asb-a polypeptides contain 6 ankyrin repeats and a SOCS box that mediate the effect of the polypeptide on the regulation of specific subsets of genes involved in differentiation. The invention discloses various methods to increase the intracellular concentration of an Asb-a polypeptide for suppression of terminal differentiation of the stem or progenitor cells. The invention further relates to Asb-a polypeptides and nucleic acids, vectors and host cells for use in methods for their production and for use in the method for expansion of stem or progenitor cells, as well as to stem or progenitor cells containing exogenous Asb-a polypeptides and nucleic acids.

Abstract translation: 本发明涉及用于扩增干细胞或祖细胞的方法。 这些方法依赖于Asb-a多肽或核酸来暂时抑制细胞的分化，从而允许干细胞或祖细胞的增殖和自我更新。 Abs-多肽和编码序列限定了在脊椎动物中在结构和功能上高度保守的一类多肽和核酸。 Asb-a多肽含有6个锚蛋白重复序列​​和SOCS盒，其介导多肽对参与分化的基因的特定亚群的调节的影响。 本发明公开了增加用于抑制干细胞或祖细胞末端分化的Asb-a多肽的细胞内浓度的各种方法。 本发明进一步涉及Asb-a多肽和核酸，载体和宿主细胞，用于其生产方法和用于扩增干细胞或祖细胞的方法，以及含有外源Asb- 多肽和核酸。

公开(公告)号：WO2004103559A3

公开(公告)日：2005-01-20

申请号：PCT/EP2004050906

申请日：2004-05-24

Applicant: UNIV AMSTERDAM ,  REEK JOOST NICOLAAS HENDRIK ,  CHEN RUIFANG ,  KAMER PAUL CLEMENS JOZEF ,  SLAGT VINCENT FRISO ,  VAN LEEUWEN PETRUS WILHELMUS N

Inventor： REEK JOOST NICOLAAS HENDRIK ,  CHEN RUIFANG ,  KAMER PAUL CLEMENS JOZEF ,  SLAGT VINCENT FRISO ,  VAN LEEUWEN PETRUS WILHELMUS N

IPC: B01J31/16 ,  B01J31/18 ,  B01J31/24 ,  C07C45/50 ,  C07C45/72 ,  C07C67/293 ,  C07C67/303 ,  C07F15/00 ,  C07F19/00

CPC classification number: B01J31/2495 ,  B01J31/069 ,  B01J31/1608 ,  B01J31/1633 ,  B01J31/165 ,  B01J31/183 ,  B01J31/189 ,  B01J31/2409 ,  B01J2219/00497 ,  B01J2219/00605 ,  B01J2219/00612 ,  B01J2219/00626 ,  B01J2219/00628 ,  B01J2219/00738 ,  B01J2231/12 ,  B01J2231/321 ,  B01J2231/342 ,  B01J2231/348 ,  B01J2231/4205 ,  B01J2231/44 ,  B01J2231/46 ,  B01J2231/52 ,  B01J2231/543 ,  B01J2231/645 ,  B01J2531/025 ,  B01J2531/0291 ,  B01J2531/26 ,  B01J2531/822 ,  B01J2531/824 ,  B01J2540/68 ,  C07C45/50 ,  C07C45/72 ,  C07C67/293 ,  C07C67/303 ,  C07F15/006 ,  C07F15/0066 ,  C07F15/0073 ,  C07F15/008 ,  Y02P20/588 ,  C07C47/228 ,  C07C69/007 ,  C07C69/34 ,  C07C69/157

Abstract: The invention relates to a coordination complex system comprising a ligand having at least two donor moieties, which are complexed to at least a metal selected from a transition metal and lanthanide, characterized in that the ligand comprises at least two building blocks, each having at least one functional group and at least one donor moiety, wherein one building block is non-covalently bonded through its functional group to a complementary functional group of another building block or of a template, wherein the template comprises at least one other functional group that is noncovalently bonded to a complementary functional group of another building block, and wherein all building blockemplate-building block structures are the same when the template contains more than two functional groups.

Abstract translation: 本发明涉及一种配位络合物体系，其包含具有至少两个供体部分的配体，其与至少一种选自过渡金属和镧系元素的金属络合，其特征在于该配体包含至少两个构建块， 一个官能团和至少一个供体部分，其中一个结构单元通过其官能团非共价键合到另一个结构单元或模板的互补官能团，其中该模板包含非共价的至少一个其它官能团 键合到另一构建块的互补官能团，并且其中当模板包含多于两个官能团时，所有构建模板构建块结构相同。

公开(公告)号：WO2004059008A2

公开(公告)日：2004-07-15

申请号：PCT/NL0300936

申请日：2003-12-24

Applicant: AZ UNIV AMSTERDAM ,  VAN KUILENBURG ANDREAS BERNARD

Inventor： VAN KUILENBURG ANDREAS BERNARD

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: The invention features methods and tools for identifying individuals having variant form of the dihydropyrimidase (DHP) gene. Variances in the DHP gene can cause intolerance to 5-fluorouracil (5-FU) and related drugs. Methods and tools for identifying variances in the DHP gene are useful for identifying patients at risk for an adverse response to 5-FU and related drugs.

Abstract translation: 本发明的特征在于鉴定具有二氢嘧啶糖苷酶（DHP）基因变体形式的个体的方法和工具。 DHP基因的差异可能导致5-氟尿嘧啶（5-FU）和相关药物的不耐受。 用于鉴定DHP基因差异的方法和工具可用于鉴定患有对5-FU和相关药物的不良反应的风险的患者。

公开(公告)号：WO0133959A3

公开(公告)日：2001-10-04

申请号：PCT/NL0000814

申请日：2000-11-08

Applicant: UNIV AMSTERDAM ,  DOORSCHOT BENEDICT MARIE ,  JASPERS JORIS EMANUEL NICOLAAS

Inventor： DOORSCHOT BENEDICT MARIE ,  JASPERS JORIS EMANUEL NICOLAAS

IPC: A01N1/02 ,  F04B43/073 ,  A61M1/00

CPC classification number: F04B43/073 ,  A01N1/02 ,  A01N1/0247

Abstract: The invention relates to an apparatus for mechanical organ perfusion during the transport phase of a donor organ, which apparatus comprises an organ receptacle for acommodating the organ, propulsion means for moving the perfusate contained in a liquid compartment of the apparatus to and through the organ receptacle, and oxygenation means for the aeration of the organ receptacle. The propulsion means are embodied as a pump driven by compressed air, while the compressed air serves at the same time for the aeration of the organ receptacle.

Abstract translation: 本发明涉及一种用于在供体器官的运输阶段期间机械器官灌注的装置，该装置包括用于调节器官的器官容器，用于将容纳在装置的液体隔室中的灌注液移动到并穿过器官容器的推进装置 以及用于器官容器充气的充氧装置。 推进装置被实施为由压缩空气驱动的泵，而压缩空气同时用于器官容器的通气。

公开(公告)号：WO9640940A3

公开(公告)日：1997-01-23

申请号：PCT/NL9600225

申请日：1996-06-06

Applicant: UNIV AMSTERDAM ,  AERTS JOHANNES MARIA FRANCISCU

Inventor： AERTS JOHANNES MARIA FRANCISCU

IPC: G01N33/50 ,  A23C9/00 ,  A23C19/00 ,  A61K8/00 ,  A61K8/66 ,  A61K8/96 ,  A61K38/00 ,  A61K38/46 ,  A61K38/47 ,  A61K39/00 ,  A61P31/00 ,  A61Q11/00 ,  C07K7/06 ,  C07K16/40 ,  C12N1/21 ,  C12N5/10 ,  C12N9/24 ,  C12N9/42 ,  C12N15/09 ,  C12N15/56 ,  C12P19/26 ,  C12P21/08 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/577 ,  A23K1/16 ,  A61K6/00 ,  A61K7/00 ,  A61K7/28 ,  C12N5/08 ,  C12N5/16 ,  G01N33/573

CPC classification number: A61K38/47 ,  A61K39/00 ,  C12N9/2442 ,  C12Y302/01014

Abstract: A new human chitinase having an amino acid sequence as shown in FIG. 1 or FIG. 2. Modified forms of it having a similar chitin-hydrolyzing activity, and antigenic peptides representing one of its epitopes. Recombinant production of the human chitinase by genetically engineered hosts or host cells. Recombinant nucleic acid encoding it, and human chitinase-specific oligonucleotides. Use for therapeutic or prophylactic treatment of humans against infection by chitin-containing pathogens, or for decomposing chitin, e.g. from chitin-based articles. Antibodies binding to the human chitinase. Diagnostic test kits comprising the human chitinase, its antigenic peptides, human chitinase antibodies, recombinant nucleic acid or oligonucleotides.